Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the
CUPISCO
Study Design
Authors
Keywords
-
Journal
ONCOLOGIST
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-11-21
DOI
10.1002/onco.13597
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers
- (2020) Vivek Subbiah et al. Cancer Discovery
- Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site
- (2019) Hidetoshi Hayashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study
- (2019) Jason K. Sicklick et al. NATURE MEDICINE
- A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability–High Cases in 67,000 Patient Samples
- (2019) Sally E. Trabucco et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials
- (2019) Yangyang Xu et al. Translational Lung Cancer Research
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- LBA10_PRClarIDHy: A global, phase III, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
- (2019) G K Abou-Alfa et al. ANNALS OF ONCOLOGY
- Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study
- (2018) John D. Hainsworth et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children
- (2018) Alexander Drilon et al. NEW ENGLAND JOURNAL OF MEDICINE
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- A computational approach to distinguish somatic vs. germline origin of genomic alterations from deep sequencing of cancer specimens without a matched normal
- (2018) James X. Sun et al. PLoS Computational Biology
- Cancer of unknown primary-Epidemiological trends and relevance of comprehensive genomic profiling
- (2018) Carmen Binder et al. Cancer Medicine
- 445TiPComprehensive profiling and molecularly guided therapy (MGT) for carcinomas of unknown primary (CUP): CUPISCO: A phase II, randomised, multicentre study comparing targeted therapy or immunotherapy with standard platinum-based chemotherapy
- (2018) A Krämer et al. ANNALS OF ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Cancer of unknown primary
- (2017) Anne-Kirstine Dyrvig et al. MEDICINE
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial
- (2017) Christophe Massard et al. Cancer Discovery
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
- (2017) Zachary R. Chalmers et al. Genome Medicine
- Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials
- (2015) Maria Schwaederle et al. JOURNAL OF CLINICAL ONCOLOGY
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- (2015) David M. Hyman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site
- (2015) Jeffrey S. Ross et al. JAMA Oncology
- Treatment of Metastatic Extramammary Paget's Disease Associated With Adnexal Adenocarcinoma, With Anti-HER2 Drugs Based on Genomic Alteration ERBB2 S310F
- (2014) O. Vornicova et al. ONCOLOGIST
- The discovery and development of vandetanib for the treatment of thyroid cancer
- (2013) Michael W Sim et al. Expert Opinion on Drug Discovery
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
- (2013) Garrett M Frampton et al. NATURE BIOTECHNOLOGY
- Loss of heterozygosity preferentially occurs in early replicating regions in cancer genomes
- (2013) B. S. Pedersen et al. NUCLEIC ACIDS RESEARCH
- Response to Cabozantinib in Patients with RET Fusion-Positive Lung Adenocarcinomas
- (2013) Alexander Drilon et al. Cancer Discovery
- Diagnostic work-up of carcinoma of unknown primary: from immunohistochemistry to molecular profiling
- (2012) K. A. Oien et al. ANNALS OF ONCOLOGY
- Cancers of unknown primary origin: current perspectives and future therapeutic strategies
- (2012) Giulia Stella et al. Journal of Translational Medicine
- Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2011) K. Fizazi et al. ANNALS OF ONCOLOGY
- Survival in cancer of unknown primary site: population-based analysis by site and histology
- (2011) K. Hemminki et al. ANNALS OF ONCOLOGY
- Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
- (2011) D. R. Borger et al. ONCOLOGIST
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now